RNA-based Therapies Show Promise in Early Studies, ReCode Reports

RNA-based Therapies Show Promise in Early Studies, ReCode Reports

296545

RNA-based Therapies Show Promise in Early Studies, ReCode Reports

RCT223 and RTX0001, ReCode Therapeutics’ experimental RNA-based therapies for cystic fibrosis (CF), safely restored function to CFTR, the faulty protein in CF, in patient-derived lung cells. Delivered through the company’s non-viral platform — called its selective organ targeting (SORT) lipid nanoparticle (LNP) platform — the therapies were also found to be well-tolerated in lung cells from patients and in mice. “Our RNA-based approaches and broad LNP platform enable us to tackle CF from multiple angles…

You must be logged in to read/download the full post.